# Sintx Technologies, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Sintx Technologies, Inc.). ## Overview SINTX Technologies is a U.S.-based advanced ceramics company focused on silicon nitride materials and components for biomedical and other technical applications. Its business combines materials research, manufacturing, and commercialization of ceramic products used in medical devices, with additional activity in coatings, aerospace-related materials, toll processing, and government-funded work. ## Products & services • Silicon nitride biomedical materials and components • Coatings, materials, and components for aerospace • Toll processing and contract manufacturing services • Government contract and grant-supported development work • Advanced ceramic R&D and product validation - **Biomedical silicon nitride products** (45%) — Medical-grade ceramic materials and components used in implant and device applications. - **Aerospace coatings and materials** (20%) — Advanced ceramic coatings, materials, and related components for aerospace uses. - **Toll processing and manufacturing services** (20%) — Contract processing and manufacturing work performed for third-party customers. - **Government contracts and grants** (15%) — Revenue tied to government-funded research, development, and contract work. - Silicon nitride biomedical materials and components - Coatings, materials, and components for aerospace - Toll processing and contract manufacturing services - Government contract and grant-supported development work - Advanced ceramic R&D and product validation ## Customers SINTX sells to medical device customers, industrial and aerospace customers, and government counterparties that fund research or contract work. In biomedical markets, buyers are typically device manufacturers seeking ceramic materials with biocompatibility, wear resistance, and antibacterial properties. In non-medical markets, customers use the company’s advanced ceramics capabilities for specialized coatings, components, and processing services. - **Medical device OEMs** (primary) — Buy silicon nitride materials and components for implant and fusion-device applications because of biocompatibility and wear properties. - **Aerospace customers** (secondary) — Buy coatings, materials, and components for technical applications where ceramic performance matters. - **Government agencies** (secondary) — Fund contract and grant work tied to research, development, and technical programs. - **Third-party manufacturers** (secondary) — Use toll processing and manufacturing support to access advanced ceramic capabilities without building them in-house. - Medical device manufacturers buying silicon nitride materials - Spine and implant OEMs seeking biocompatible ceramic inputs - Aerospace customers needing coatings and ceramic components - Government agencies funding research and contract work - Third-party manufacturers outsourcing toll processing ## Geography SINTX is headquartered in the United States and serves customers across multiple regions through its biomedical and technical ceramics activities. Its spinal implant materials have been used in humans in the U.S., Europe, South America, and Asia, indicating an international end-market footprint even though the company’s operating base is U.S.-centric. Geography matters because medical device adoption, regulatory pathways, and customer qualification cycles differ by region. - Headquartered and operated from the United States - Medical implant use has extended into Europe, South America, and Asia - U.S. market is important for medical device and government work - International adoption depends on local regulatory and OEM qualification - Aerospace and industrial customers may be served through U.S. operations ## Strategy SINTX’s strategy is to leverage its silicon nitride and advanced ceramics expertise across biomedical, aerospace, and other technical markets. The company is focused on expanding third-party manufacturing opportunities, developing new products, and using research and validation work to broaden commercial adoption of its materials platform. - **Commercialize silicon nitride in more device categories** (medium-term) — Broader adoption increases the addressable market for the company’s core material platform. - **Secure third-party manufacturing and toll processing work** (short-term) — These relationships can convert technical capability into recurring product and service revenue. - **Develop non-medical advanced ceramics applications** (medium-term) — Diversification can reduce dependence on a single end market and expand customer reach. - Expand silicon nitride commercialization beyond core medical uses - Win third-party manufacturing opportunities for ceramic products - Use R&D and validation to support new product introductions - Broaden into aerospace and other technical applications - Pursue customer, partner, and manufacturer relationships ## Risks SINTX faces the typical risks of a development-stage materials company, including dependence on customer adoption, regulatory and validation timelines, and the need for continued funding. Its business also carries concentration risk in a small number of product and contract categories, while technical performance, manufacturing scale-up, and reimbursement or qualification hurdles can delay commercialization. - **Need for additional capital** [high] — The company states it will require substantial future capital to fund development and commercialization. - **Commercial adoption risk** [high] — Revenue depends on customers qualifying and adopting silicon nitride and related products. - **Regulatory and clinical validation risk** [high] — Biomedical products must clear technical, clinical, and regulatory hurdles before broad use. - **Revenue concentration and volatility** [medium] — Grant and contract revenue can fluctuate materially with award timing and project disposition. - Going-concern and financing risk if capital access tightens - Customer adoption risk for new medical and industrial products - Regulatory and validation risk for medical device applications - Manufacturing scale-up risk for advanced ceramic products - Revenue volatility from grants, contracts, and small order volumes ## Accounting Revenue is recognized at a point in time when control transfers, typically on shipment, which makes order timing and customer mix important for quarterly comparability. Investors should also watch estimates tied to income taxes, derivative liabilities, asset impairment, and collectability, as these can materially affect reported results in a company with limited scale and volatile operating performance. - **Revenue recognition timing** — Quarterly revenue comparability - **Grant and contract revenue** — Revenue volatility - **Derivative liabilities** — Net income volatility - **Asset impairment and collectability** — Balance sheet and earnings estimates - Point-in-time revenue recognition on shipment affects quarterly timing - Grant and contract revenue can be uneven based on award activity - Derivative liability valuation can move earnings through fair value changes - Asset impairment judgments matter for specialized equipment and intangibles - Collectability estimates affect receivables and reported earnings --- *Last updated: 2026-04-29T04:58:47.549639+00:00*